Supernus Pharmaceuticals SUPN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's additional paid-in capital?
- Supernus Pharmaceuticals (SUPN) reported additional paid-in capital of $561.42M in Q1 2026.
- How has Supernus Pharmaceuticals's additional paid-in capital changed year-over-year?
- Supernus Pharmaceuticals's additional paid-in capital increased by 15.5% year-over-year, from $486.21M to $561.42M.
- What is the long-term trend for Supernus Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's additional paid-in capital has grown at a 5.8% compound annual growth rate (CAGR), from $409.33M to $543.83M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.